{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:25:31Z","timestamp":1760887531668},"reference-count":57,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.vaccine.2004.06.054","type":"journal-article","created":{"date-parts":[[2004,9,22]],"date-time":"2004-09-22T16:16:26Z","timestamp":1095869786000},"page":"1189-1196","source":"Crossref","is-referenced-by-count":14,"title":["Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis"],"prefix":"10.1016","volume":"23","author":[{"given":"Ravendra","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Dube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.06.054_bib1","unstructured":"WHO. Antimonials: large scale failure in leishmaniasis is alarming. TDR News 1990;34:1\u20137."},{"key":"10.1016\/j.vaccine.2004.06.054_bib2","unstructured":"WHO. Advances in battle against leishmaniasis. TDR News 1998; 34:1\u20137."},{"issue":"11","key":"10.1016\/j.vaccine.2004.06.054_bib3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop Med Int Health"},{"issue":"4","key":"10.1016\/j.vaccine.2004.06.054_bib4","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2004.06.054_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0169-4758(97)01060-0","article-title":"Leishmania vaccines: old and new","volume":"13","author":"Handman","year":"1997","journal-title":"Parasitol Today"},{"issue":"8530","key":"10.1016\/j.vaccine.2004.06.054_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(87)90116-4","article-title":"Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis","volume":"1","author":"Convit","year":"1987","journal-title":"Lancet"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2004.06.054_bib7","first-page":"159","article-title":"Immunotherapy as treatment of American cutaneous leishmaniasis: preliminary studies in Brazil","volume":"34","author":"Mayrink","year":"1992","journal-title":"Parasitologia"},{"issue":"9241","key":"10.1016\/j.vaccine.2004.06.054_bib8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(00)03128-7","article-title":"Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double blind. BCG-controlled trial in Sudan","volume":"356","author":"Khalil","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2004.06.054_bib9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","article-title":"Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania donovani","volume":"186","author":"Gurunathan","year":"1997","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.vaccine.2004.06.054_bib10","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.4049\/jimmunol.147.10.3538","article-title":"The Leishmania donovani lipophosphogrycan T lymphocyte reactive component is a tightly associated protein complex","volume":"147","author":"Jardim","year":"1991","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2004.06.054_bib11","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.4049\/jimmunol.161.11.6171","article-title":"LeIF: a recombinant Leishmania protein that induces IL-12-mediated TH1 cytokine proffle","volume":"161","author":"Skeiky","year":"1998","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2004.06.054_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.144.2.699","article-title":"Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis","volume":"144","author":"Jaffe","year":"1990","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2004.06.054_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00193391","article-title":"Immunology of experimental leishmaniasis","volume":"181","author":"Muller","year":"1992","journal-title":"Med Microbiol Immunol"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2004.06.054_bib14","first-page":"1068","article-title":"A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante RN)","volume":"19","author":"Da Silva","year":"2001","journal-title":"Vaccine"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2004.06.054_bib15","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0264-410X(02)00294-3","article-title":"Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante, RN)","volume":"20","author":"Borja-Cabrera","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.06.054_bib16","first-page":"290","article-title":"The FML vaccine (fucose-mannose ligand) protects hamsters from experimental Kala-Azar","volume":"46","author":"Palatnik de Sousa","year":"1994","journal-title":"Ciencia e Cultura (J Braz Assoc Adv Sci)"},{"key":"10.1016\/j.vaccine.2004.06.054_bib17","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/S0264-410X(99)00058-4","article-title":"Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model","volume":"17","author":"Santos","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.06.054_bib18","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.06.054_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"21","author":"Santos","year":"2002","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2004.06.054_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1550-7408.1980.tb04676.x","article-title":"Isolation and partial characterisation of surface membranes from Leishmania donovani promastigotes","volume":"27","author":"Dwyer","year":"1980","journal-title":"J Protozool"},{"issue":"8","key":"10.1016\/j.vaccine.2004.06.054_bib21","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/IAI.61.8.3351-3359.1993","article-title":"Recombinant vaccinia viruses expressing gp46\/M-2 protects against leishmania infection","volume":"61","author":"McMahon-Pratt","year":"1993","journal-title":"Infect Immun"},{"issue":"24","key":"10.1016\/j.vaccine.2004.06.054_bib22","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.90.24.11473","article-title":"Effective immunization against cutaneous leishmaniasis with recombinant Bacillus Calmette-Guerin expressing the Leishmania surface proteinase gp63","volume":"90","author":"Connell","year":"1993","journal-title":"Proc Nat Acad Sci USA"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2004.06.054_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0001-706X(94)90028-0","article-title":"Evaluation of recombinant gp63, the major Leishmania surface glycoprotein as a diagnostic molecule of leishmaniasis in vervet monkeys","volume":"58","author":"Gicheru","year":"1994","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2004.06.054_bib24","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/IAI.56.12.3272-3279.1988","article-title":"Membrane glyeoprotein M-2 protects against Leishmania amazonensis infection","volume":"56","author":"Champsi","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.06.054_bib25","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1073\/pnas.82.17.5910","article-title":"Immunization with leishmania receptor for macrophages protects mice against cutaneous leishmaniasis","volume":"82","author":"Handman","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2004.06.054_bib26","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1073\/pnas.84.24.8941","article-title":"Lipophosphoglycon of Leishmania major that vaccinate against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor","volume":"84","author":"Mc Conville","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2004.06.054_bib27","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/S0021-9258(19)69848-0","article-title":"Phase separation of integral membrane proteins in Triton X-114 solution","volume":"256","author":"Bordier","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2004.06.054_bib28","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1128\/IAI.66.5.2135-2142.1998","article-title":"Cloning of syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis","volume":"66","author":"Melby","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.06.054_bib29","first-page":"289","article-title":"Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis","volume":"17","author":"Mukhopadhyay","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.06.054_bib30","first-page":"355","article-title":"Cultivation of various Leishmania parasites on solid medium","volume":"20","author":"Ray","year":"1932","journal-title":"Ind. J. Med. Res."},{"key":"10.1016\/j.vaccine.2004.06.054_bib31","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1073\/pnas.85.14.5195","article-title":"Identification of two integral membrane proteins of Plasmodium falciparum","volume":"85","author":"Smyth","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2004.06.054_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with folin-phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2004.06.054_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0035-9203(90)90319-A","article-title":"Enzyme linked immunosorbant assay in diagnosis of kala-azar in Bhadohi (Varanasi) India","volume":"84","author":"Choudhury","year":"1990","journal-title":"Trans Roy Soc Trop Med Hyg"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2004.06.054_bib34","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/S0264-410X(01)00058-5","article-title":"Successful vaccination against Leishmania donvoani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG","volume":"19","author":"Mishra","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.06.054_bib35","series-title":"The enzyme linked immunosorbant assay (ELISA): a guide with abstracts of microplate application","author":"Voller","year":"1979"},{"issue":"8","key":"10.1016\/j.vaccine.2004.06.054_bib36","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.4049\/jimmunol.146.8.2763","article-title":"Differential production of Th-1 and Th-2 derived cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine visceral leishmaniasis","volume":"146","author":"Kaye","year":"1991","journal-title":"J Immunol"},{"issue":"5144","key":"10.1016\/j.vaccine.2004.06.054_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.vaccine.2004.06.054_bib38","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.4049\/jimmunol.142.12.4441","article-title":"Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen liposomes. Optimization and assessment of the requirement for intravenous immunizaiton","volume":"142","author":"Kahl","year":"1989","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2004.06.054_bib39","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/IAI.56.12.3272-3279.1988","article-title":"Membrane glycoprotein M-2 protects against Leishmania amazonensis infection","volume":"56","author":"Champsi","year":"1988","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2004.06.054_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0166-6851(87)90028-4","article-title":"Cloning of a gene encoding the immunodominant surface antigen of Leishmania donovani promastigotes","volume":"23","author":"Heath","year":"1987","journal-title":"Mol Biochem Parasitol"},{"issue":"2","key":"10.1016\/j.vaccine.2004.06.054_bib41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.144.2.699","article-title":"Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis","volume":"144","author":"Jaffe","year":"1990","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2004.06.054_bib42","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/infdis\/161.6.1313","article-title":"Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine","volume":"161","author":"White","year":"1990","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2004.06.054_bib43","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1128\/IAI.57.7.2203-2209.1989","article-title":"Characterisation of integral membrane proteins of Leishmania major by Triton X-114. Production and analysis of vaccination effect in mice","volume":"57","author":"Murray","year":"1989","journal-title":"Infect. Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2004.06.054_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0166-6851(88)90122-3","article-title":"Immunoblotting analysis of the major integral membrane protein antigens of Schistosoma japonicum","volume":"29","author":"Rogers","year":"1988","journal-title":"Mol Biochem Parasitol"},{"issue":"2","key":"10.1016\/j.vaccine.2004.06.054_bib45","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0014-4894(88)90134-8","article-title":"Trypanosoma brucei gambiense: pantidioning of glyco peptides of blood stream and procyclic forms in Triton X-114","volume":"65","author":"Balber","year":"1988","journal-title":"Exp Parasitol"},{"issue":"2","key":"10.1016\/j.vaccine.2004.06.054_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0304-4157(76)90009-5","article-title":"Characterisation of membrane proteins in detergent solutions","volume":"457","author":"Tanford","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2004.06.054_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/CDLI.7.2.233-240.2000","article-title":"Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis","volume":"7","author":"Mukhopadhyay","year":"2000","journal-title":"Clin Diagnos Lab Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2004.06.054_bib48","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/IAI.65.6.2371-2377.1997","article-title":"Adjuvanticity and protective immunity elicited by Leishmania donovani antigens incapsulated in positively charge liposomes","volume":"65","author":"Afrin","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.06.054_bib49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.vaccine.2004.06.054_bib50","doi-asserted-by":"crossref","first-page":"762","DOI":"10.4269\/ajtmh.1981.30.762","article-title":"Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes","volume":"30","author":"Holbrook","year":"1981","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2004.06.054_bib51","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/IAI.42.2.702-707.1983","article-title":"Cell mediated immune response in Indian kala-azar and post kala-azar dermal leishmaniasis","volume":"42","author":"Haldar","year":"1983","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2004.06.054_bib52","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/eji.1830220813","article-title":"Immunobiological studies on experimental visceral leishmaniasis. II. Adherent cell mediated down regulation of delayed type hypersensitivity response and up-regulation of B-cell activation","volume":"22","author":"Basak","year":"1992","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2004.06.054_bib53","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4049\/jimmunol.144.3.1075","article-title":"Protection against leishmania major in Balb\/c mice by adoptive transfer of a T-cell clone recognizing a low molecular weight antigen released by promastigotes","volume":"144","author":"Scott","year":"1990","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2004.06.054_bib54","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.4049\/jimmunol.140.4.1274","article-title":"Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes","volume":"140","author":"Russel","year":"1988","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2004.06.054_bib55","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.4049\/jimmunol.133.3.1594","article-title":"Exacerbation of cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T-cell populations capable of mediating Leishmania major specific delayed type hypersensitivity","volume":"133","author":"Titus","year":"1984","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2004.06.054_bib56","first-page":"318","article-title":"Serological investigations on Indian Kala-azar","volume":"40","author":"Ghose","year":"1980","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2004.06.054_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/clinids\/22.1.1","article-title":"A clinical spectrum of leishmaniasis","volume":"22","author":"Pearson","year":"1996","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04006449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04006449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T10:26:47Z","timestamp":1682764007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04006449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0264410X04006449"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.06.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}